证券日报网讯 瑞普生物9月12日发布公告，在公司回答调研者提问时表示，为推动原料药板块提质增 效，公司重点实施三大关键举措：一是深化精益降本，通过对产品生产工艺、全生产流程开展精准诊断 优化，并加强集中采购管理，有效降低单位生产成本；二是加速海外市场拓展，继续扩大出口份额；三 是优化产品结构，提升高毛利产品占比，下半年还将推出盐酸沃尼妙林二水合物、头孢噻呋晶体等新产 品，进一步丰富高附加值产品矩阵，以提高综合盈利水平。 （编辑 袁冠琳） ...

Competitive Advantages - Reap Bio is one of the largest and most comprehensive veterinary drug companies in China, with significant R&D advantages, including 117 new veterinary drug registration certificates and an annual R&D investment exceeding 100 million RMB [2][3] - The company has a full product line system that provides a closed-loop service from detection to clinical validation, helping to reduce costs and improve efficiency for clients [2][3] - The company has a notable first-mover advantage in the pet medicine sector, with 17 new veterinary drug registration certificates for pets and strategic layouts in innovative drugs and mRNA vaccines [3] Strategic Development - Reap Bio is focusing on high-quality development driven by innovation, accelerating the development of third-generation vaccines and new drugs, and deepening strategic cooperation with breeding groups [3][4] - The company is actively pursuing internationalization and exploring potential sectors such as synthetic biology to create new growth drivers [3][4] Product Launches and Innovations - Key products to be launched in the second half of 2025 include new vaccines and long-acting formulations, aimed at addressing core diseases in poultry farming [7][8] - The company is also expanding its product matrix in the pet sector with new offerings such as cat interferon and probiotics, enhancing its comprehensive product range [7][8] Financial Performance - In the first half of 2025, the company reported revenue of 1.708 billion RMB and a net profit of 257 million RMB, representing year-on-year growth of 20.53% and 57.59% respectively [14] - The company has repurchased 10.68 million shares, with a total repurchase amount of 1.9 billion RMB, maintaining a cash dividend payout ratio of 44.32% [14] Market Position and Future Outlook - The company is committed to maintaining its market position in the pet medical sector and is exploring potential mergers and acquisitions to strengthen its competitive edge [12][13] - Reap Bio is also focusing on enhancing its online sales channels and integrating its products with pet hospitals to increase customer traffic and sales [7][8]

Core Insights - The company reported significant improvement in the raw material drug sector, reducing losses by over 10 million yuan compared to the same period last year [1] Group 1: Key Initiatives - The company is implementing three key measures to enhance the performance of the raw material drug sector: 1. Deepening lean cost reduction by optimizing production processes and enhancing centralized procurement management to effectively lower unit production costs [1] 2. Accelerating overseas market expansion to continue increasing export share [1] 3. Optimizing product structure to increase the proportion of high-margin products, with plans to launch new products such as hydrochloride voriconazole dihydrate and cefotaxime crystals in the second half of the year to enrich the high value-added product matrix [1]